

CLEAN VERSION OF REWRITTEN OR ADDED CLAIMS
PURSUANT TO 37 CFR § 1.21 (c)(1)(i)


Please amend the following claims.

BEST AVAILABLE COPY

01 E1 22. (Twice Amended) A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is aerosolized for administration to a subject.

02 E2 28. (Twice Amended) A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in a an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope for intratracheal administration to a subject.

03 E3 33. (Amended) A composition for the treatment of a microbial infection comprising, a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.



COPY OF PAPERS
ORIGINALLY FILED

PATENT
Attorney Docket No. UM-03663

RECEIVED
SEP 23 2002
FBI/DOJ
TECH CENTER 1000 2800

RECEIVED

APPENDIX II
CLEAN VERSION OF THE ENTIRE SET OF PENDING CLAIMS
PURSUANT TO 37 CFR § 1.121 (c)(3)

BEST AVAILABLE COPY

22. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is aerosolized for administration to a subject.
23. The solution of Claim 22, wherein said leukotriene is leukotriene B₄.
24. The solution of Claim 22, wherein said leukotriene is a cysteinyl leukotriene.
25. The solution of Claim 24, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄, and leukotriene E₄.
27. The solution of Claim 22, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.
28. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope for intratracheal administration to a subject.
29. The solution of Claim 28, wherein said leukotriene is leukotriene B₄.
30. The solution of Claim 28, wherein said leukotriene is a cysteinyl leukotriene.
31. The solution of Claim 28, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄, and leukotriene E₄.

32. The solution of Claim 28, wherein said microbial infection comprises *Klebsiella pneumoniae* infection. BEST AVAILABLE COPY
33. A composition for the treatment of a microbial infection comprising, a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.
34. The composition of Claim 33, wherein said leukotriene is leukotriene B₄.
35. The composition of Claim 33, wherein said leukotriene is cysteinyl leukotriene.
36. The composition of Claim 33, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄ and leukotriene E₄.
37. The composition of Claim 33, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.